Winston Pharmaceuticals (Winston Pharmaceuticals) ROCE % : -667.15% (As of Mar. 2010)

View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Winston Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2010 was -667.15%.

Winston Pharmaceuticals ROCE % Historical Data

The historical data trend for Winston Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals ROCE % Chart

Winston Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Dec08

Dec09

ROCE %

-13.35

-147.92

-147.33

Winston Pharmaceuticals Quarterly Data
	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10
ROCE %	Get a 7-Day Free Trial														-115.77	-141.16	-209.54	-300.94	-667.15

Winston Pharmaceuticals ROCE % Calculation

Winston Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2009 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2009 )		(A: Dec. 2008 )		(A: Dec. 2009 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2009 )		(A: Dec. 2008 )		(A: Dec. 2009 )
	=	-2.741	/	( ( (5.791 - 2.559)	+	(1.676 - 1.187) )	/ 2 )
	=	-2.741	/	( (3.232	+	0.489)	/ 2 )
	=	-2.741	/	1.8605
	=	-147.33 %

Winston Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2010 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2010 )		(Q: Dec. 2009 )		(Q: Mar. 2010 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2010 )		(Q: Dec. 2009 )		(Q: Mar. 2010 )
	=	-1.848	/	( ( (1.676 - 1.187)	+	(0.842 - 0.777) )	/ 2 )
	=	-1.848	/	( ( 0.489	+	0.065 )	/ 2 )
	=	-1.848	/	0.277
	=	-667.15 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2010) EBIT data.

Winston Pharmaceuticals (GREY:WPHM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Winston Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061

Website

http://www.winstonlabs.com

Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri	director	4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser	10 percent owner	1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver	director, officer: Vice President	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg	director, officer: Chief Financial Officer	2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel	10 percent owner	4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines